Adaptimmune Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Revenue - Collaboration Agreement - The Astellas Collaboration Agreement (Details)

Revenue - Collaboration Agreement - The Astellas Collaboration Agreement (Details) - Astellas Collaboration Agreement. - USD ($)	Mar. 06, 2022	Dec. 31, 2023
Revenue
Amount of termination penalties in connection with the termination.	$ 0
Aggregate transaction price of the contract modification		$ 42,365,000
Maximum
Revenue
Number of days the company is entitled to receive reimbursement after termination.	30 days

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details